GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLight Life Sciences Ltd (NAS:BOLT) » Definitions » Debt-to-Asset

BioLight Life Sciences (BioLight Life Sciences) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BioLight Life Sciences Debt-to-Asset?

BioLight Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil. BioLight Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BioLight Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $8.74 Mil. BioLight Life Sciences's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


BioLight Life Sciences Debt-to-Asset Historical Data

The historical data trend for BioLight Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLight Life Sciences Debt-to-Asset Chart

BioLight Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

BioLight Life Sciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 - -

Competitive Comparison of BioLight Life Sciences's Debt-to-Asset

For the Biotechnology subindustry, BioLight Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLight Life Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLight Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BioLight Life Sciences's Debt-to-Asset falls into.



BioLight Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BioLight Life Sciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

BioLight Life Sciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLight Life Sciences  (NAS:BOLT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


BioLight Life Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BioLight Life Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLight Life Sciences (BioLight Life Sciences) Business Description

Traded in Other Exchanges
Address
Kiryat Atidim, Building 7, Entrance 1, 2nd Floor, Tel-Aviv, ISR, 6158101
BioLight Life Sciences Ltd is an emerging global ophthalmic company. It is engaged in the discovery, development, and commercialization of products and product candidates which address ophthalmic conditions, including glaucoma, dry eye syndrome and age-related macular degeneration. The firm's products include ioptimate, eye-d technology, and diagnostear. The company has the Eye cluster and the Cancer diagnostics cluster operating segments. It derives the majority of its revenues from the Eye cluster segment.